Full Extent Of Clinical Trial Damage May Be Unknown Until Pandemic Ends, CBER’s Peter Marks Says
Executive Summary
More patient-centric trial designs also may be coming due to pandemic-related advances, Marks says.
You may also be interested in...
Pandemic Perspectives: US FDA, NIH Tried To Be Flexible To Keep Rare Disease Trials Going
Both federal agencies extended grants to help investigators adapt to the changes mandated by the COVID-19 pandemic.
As Pandemic Delays Reduce PDUFA Revenues, US FDA Slows Fee-Related Spending
Agency cites “unexpected and large drop in collections” in slashing user-fee-setting contract.
FDA’s COVID-19 Pandemic Plan Calls For Ongoing Clinical Trial Innovation
Broader use of adaptive trial designs and master protocols, checklist-based application review, and enhancement of real-world monitoring of products are among the recommendations of US FDA's COVID-19 Pandemic Recovery and Preparedness Plan (PREPP) report, an effort months in making based on interviews with agency management, staff, and outside stakeholders.